Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.52 |
| ▸ | JAK1 | P23458 | 7/20 | 0.52 |
| ▸ | TYK2 | P29597 | 7/20 | 0.52 |
| ▸ | JAK3 | P52333 | 6/20 | 0.52 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6068484 | 0.92 | JAK2 (0.47) | JAK2JAK1TYK2JAK3PARP1 | |
| SCHEMBL5458391 | 0.83 | JAK2 (0.75) | JAK2JAK1TYK2JAK3PARP1 | |
| SCHEMBL1926925 | 0.76 | IKBKB (0.56) | JAK2PDK1TBK1PARP1HRH3 | |
| SCHEMBL3510941 | 0.76 | CHEK1 (0.56) | JAK2JAK1TYK2JAK3PDK1 | |
| SCHEMBL5237983 | 0.76 | IKBKB (0.51) | JAK2JAK1TYK2JAK3TBK1 | |
| SCHEMBL6401995 | 0.75 | JAK2 (0.51) | JAK2JAK1TYK2JAK3CHEK1 | |
| SCHEMBL29012217 | 0.71 | CHEK1 (0.42) | JAK2GRM2CHEK1 | |
| SCHEMBL1928109 | 0.71 | CHEK1 (0.80) | JAK2JAK3KCNH2CHEK1 | |
| SCHEMBL1928700 | 0.71 | MAP3K7 (0.70) | TBK1PARP1HRH3CHEK1 | |
| SCHEMBL12832077 | 0.71 | MAP4K4 (0.44) | JAK2JAK1TYK2JAK3PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272730-A1 | Thienopyridazines as IKK inhibitors | ROCHE PALO ALTO LLC | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272730-A1 | Thienopyridazines as IKK inhibitors | IKBKE, IKBKB, NFKBIA | JAK2 77/4885JAK1 37/4885TYK2 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.